Biological E. Limited (BE), established in 1953, is one of India’s pioneering and leading vaccine and biologics manufacturing companies. With over seven decades of experience, BE has been a trusted partner in global public health—supplying vaccines to national immunization programs, UNICEF, and over 140 countries worldwide. To date, BE has delivered more than five billion doses globally, making a significant impact on global health.
BE’s robust vaccine portfolio includes 13 licensed vaccines, 11 of which are WHO pre-qualified, such as the CORBEVAX™ COVID-19 vaccine (listed under WHO’s Emergency Use Listing) and the 14-valent Pneumococcal Conjugate Vaccine (PCV-14), currently under WHO review for prequalification.
Our state-of-the-art infrastructure includes cutting-edge R&D centers, GMP-compliant manufacturing facilities, and a strong workforce of over 5,000 skilled professionals, including 350+ scientists. BE’s facilities meet the highest global regulatory standards, including USFDA, EMEA, WHO, ANVISA (Brazil), and TGA (Australia), among others.
BE’s integrated development and manufacturing platform spans a wide spectrum of technologies, including:
BE offers end-to-end solutions for biologics and vaccines, covering:
Our core strengths in technology transfer, co-development, and in-licensing enable us to bring innovative therapies to market faster—particularly in the areas of next-generation vaccines and RNA-based therapeutics.
At the World Vaccine Congress Europe 2025, we look forward to engaging in impactful discussions and fostering strategic partnerships with like-minded organizations committed to advancing global health.